CEACAM5 and colorectal carcinoma: These observations indicate that CEA heterogeneity and plasticity may serve as predictive biomarkers for clinical outcomes and suggest that combining WNT/β-catenin pathway inhibitors with cibisatamab represents a rational therapeutic approach to improve CRC immunotherapy efficacy.